A Phase 1/2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Subjects
Latest Information Update: 07 Nov 2023
At a glance
- Drugs GX 19N (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Genexine
- 25 Nov 2021 Planned End Date changed from 30 Mar 2022 to 30 Jun 2022.
- 25 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 21 Jan 2021 New trial record